社区获得性肺炎患者接种肺炎球菌结合疫苗的应答:肺炎链球菌与其他病原体感染者的差异
研究纳入60例住院社区获得性肺炎康复者(34例肺炎链球菌肺炎,26例其他明确病原体肺炎),接种13价肺炎球菌结合疫苗(PCV13)后3-4周检测血清型特异性抗体。肺炎链球菌组完全应答者比例显著低于其他病原体组(15% vs 42%,p=0.02),血清型1的总IgG及IgG2/IgG1亚类抗体浓度显著更低,但两组良好应答者比例相近(74% vs 77%)。
要点
- 肺炎链球菌肺炎康复者接种PCV13后完全应答率低于其他病原体肺炎康复者(15% vs 42%,p=0.02)。
- 两组良好应答者比例相近(74% vs 77%)。
- 血清型1的总IgG及IgG2/IgG1亚类接种后浓度在肺炎链球菌组显著更低。
核心结论
- 结果证实PCV13在既往肺炎链球菌社区获得性肺炎患者中具有免疫原性,包括既往被视为潜在低应答者的患者。
- 既往肺炎链球菌社区获得性肺炎患者对多糖的总体体液应答略有减弱。
研究设计与样本
- 筛选参加两项试验(2004-2006年,n=201;2007-2009年,n=304)的住院成人社区获得性肺炎患者。
- 纳入标准为肺炎链球菌所致社区获得性肺炎(pneuCAP)或其他明确病原体所致社区获得性肺炎(otherCAP)。
- 共接种60例患者:34例pneuCAP和26例otherCAP。
- 接种PCV13前及接种后3-4周采用Luminex法检测血清型特异性肺炎球菌抗体浓度(总IgG及IgG2/IgG1)。
主要发现
- pneuCAP组良好应答者(≥9/13个血清型浓度≥1300ng/ml)占74%,otherCAP组占77%。
- pneuCAP组完全应答者(13/13个血清型浓度≥1300ng/mL)占15%,显著少于otherCAP组的42%(p=0.02)。
- 血清型1的总IgG及IgG2/IgG1亚类接种后浓度在pneuCAP患者中显著更低。
- 补充病例系列显示,16例曾感染PCV13所含血清型的pneuCAP患者中,3例对原感染血清型无应答,其中1例既往菌血症性肺炎链球菌肺炎患者在感染期间对该血清型也无应答。
- 13例在接种PCV13后对既往感染血清型有应答,其中包括3例菌血症性肺炎链球菌肺炎患者在感染期间对该血清型无应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of this study is to investigate the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in former pneumococcal CAP patients. We hypothesize that an impaired or suboptimal humoral immune response against (specific) pneumococcal serotypes might explain the vulnerability for pneumococcal disease. METHODS: Hospitalised adult CAP patients who participated in two trials (2004-2006 (n=201) and, 2007-2009 (n=304)) were screened. Patients eligible for inclusion had CAP caused by either S. pneumoniae (pneuCAP) or due to another well-defined pathogen (otherCAP). Serotype-specific pneumococcal antibody concentrations (total IgG and IgG2/IgG1) before and 3-4weeks after PCV13 administration were measured (Luminex) and compared between pneuCAP and otherCAP patients. RESULTS: We vaccinated 60 patients:i.e. 34 pneuCAP and 26 otherCAP patients. In the pneuCAP group, 74% of patients were categorized as good responders (≥9/13 serotypes with concentration≥1300ng/ml), versus 77% in the otherCAP group. Significantly fewer full responders (i.e. 13/13 serotypes with a concentration≥1300ng/mL) were identified in the pneuCAP group (15% vs 42% respectively, p=0.02). For serotype 1, total IgG and IgG2/IgG1 subset post-vaccination concentrations were significantly lower among pneuCAP patients. Our additional case-series showed that of 16 pneuCAP patients who were infected by a serotype included in PCV13 three patients did not respond against the serotype originally responsible for their CAP episode, including one former bacteraemic pneumococcal CAP patient who also failed to show a response against the serotype responsible for CAP during infection. Thirteen patients did respond to the previously infecting serotype following PCV13 including three patients who had bacteraemic pneumococcal pneumonia and did not show a response during infection against the serotype responsible for CAP. CONCLUSIONS: Our results confirm the immunogenic properties of PCV13 in former pneumococcal CAP patients including patients previously regarded as potential hyporesponders. A slightly diminished overall humoral response to polysaccharides characterizes the former pneumococcal CAP patients. ClinicalTrials.gov Identifier: NCT02141009.
引用
- Wagenvoort GHJ, Vlaminckx BJM, van Kessel DA, et al. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens. Vaccine. 2017. PMID: 28802755. doi:10.1016/j.vaccine.2017.07.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。